Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study

被引：1

作者：

Mohan, K. ^{[1
]}

Prajapati, A. ^{[2
]}

Kothari, R. K. ^{[3
]}

Mondal, S. ^{[4
]}

Nagarkar, R. ^{[5
]}

Kane, S. B. ^{[6
]}

Santa, A. ^{[1
]}

Dadke, D. ^{[7
]}

机构：

[1] Basavatarakam Indo Amer Canc Hosp & Res Inst, Med Oncol, Hyderabad, India

[2] Curateq Biol Private Ltd, Clin Dev, Hyderabad, India

[3] Narayana Multispecialty Hosp, Med Oncol, Ahmadabad, Gujarat, India

[4] Nilratan Sircar Med Coll & Hosp, Radiotherapy, Kolkata, India

[5] HCG Manavata Canc Ctr, Surg Oncol, Nasik, India

[6] RST Reg Canc Ctr, Med Oncol, Nagpur, Maharashtra, India

[7] Curateq Biol Private Ltd, Hyderabad, India

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.201

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

67P

引用

页码：S1491 / S1491

页数：1

共 50 条

[41] Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study
Masataka Sawaki
Hirofumi Mukai
Nahomi Tokudome
Takahiro Nakayama
Naruto Taira
Toshiro Mizuno
Yutaka Yamamoto
Akiyo Horio
Toru Watanabe
Yukari Uemura
Yasuo Ohashi
Breast Cancer, 2012, 19 : 253 - 258
[42] First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study
Andreis, D.
Scandurra, G.
Santini, D.
Gucciardino, C.
La Verde, N. M.
Girelli, S.
Alabiso, I.
Saetta, A.
Atzori, F.
Collova, E.
Ferzi, A.
Gori, S.
Lipari, H.
Saggia, C.
Marcon, I.
Generali, D. G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[43] CARDIAC SAFETY OF THE TRASTUZUMAB BIOSIMILAR ABP 980 IN WOMEN WITH HER2-POSITIVE EARLY BREAST CANCER IN THE LILAC STUDY
Kolberg, H-C
Colleoni, M.
Demetriou, G. Sawa
Santi, P.
Tesch, H.
Fujiwara, Y.
Tomasevic, Z.
Hanes, V.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A55 - A55
[44] Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Cortes Castan, J.
Pegram, M.
Pivot, X.
Curigliano, G.
Lim, J. Y.
Song, S.
Yoon, Y. C.
ANNALS OF ONCOLOGY, 2018, 29
[45] High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer:: A phase II study
Stemmler, HJ
Kahlert, S
Brudler, O
Beha, M
Müller, S
Stauch, B
Heinemann, V
CLINICAL ONCOLOGY, 2005, 17 (08) : 630 - 635
[46] Trastuzumab Biosimilar for Patients with HER2-positive Breast Cancer and Stomach Cancer Effective and economical Treatment with a new Trastuzumab Biosimilar
不详
BREAST CARE, 2019, 14 (04) : 260 - 261
[47] Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
You, Shuhui
Xie, Yizhao
Sang, Die
Luo, Ting
Yuan, Peng
Xu, Fei
Wang, Biyun
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[48] Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.
Sato N.
Sano M.
Tabei T.
Asaga T.
Ando J.
Fujii H.
Yamamoto N.
Kurosumi M.
Inoue K.
Kimura M.
Breast Cancer, 2006, 13 (2) : 166 - 171
[49] A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+AR+ metastatic or locally advanced breast cancer
Krop, I.
Cortes, J.
Miller, K.
Huizing, M. T.
Provencher, L.
Gianni, L.
Chan, S.
Trudeau, M.
Steinberg, J.
Ugg, J. S.
Liosatos, M.
Paton, V. E.
Peterson, A.
Wardley, A.
CANCER RESEARCH, 2017, 77
[50] Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study
Zhang, Ruyan
Liu, Xiaoran
Song, Guohong
Zhang, Yan
Li, Huiping
CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 795 - 801

← 1 2 3 4 5 →